18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
50
Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGStandardized uptake value of 18F-FES in BC
The max standard uptake value (SUVmax) was measured in the breast cancer lesions on 18F-FES PET/CT.
Time frame: through study completion, an average of 1 year
Lesions detected by 18F-FES PET/CT
The number of target lesions was calculated by 18F-FES PET/CT.
Time frame: through study completion, an average of 1 year
Compared with 18F-FDG PET/CT
The number of lesions detected by 18F-FES PET/CT was compared with 18F-FDG PET/CT.
Time frame: through study completion, an average of 1 year
Overall survival
Evaluate overall survival (OS) in patients receiving regimens containing endocrine therapy
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.